PART I - FINANCIAL INFORMATION This part presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis of financial condition and results of operations Item 1. Condensed Consolidated Financial Statements This section presents the unaudited condensed consolidated financial statements and notes, highlighting a significant net loss and asset decrease due to impairment losses Condensed Consolidated Balance Sheets The balance sheet shows a decrease in total assets and stockholders' equity as of June 30, 2025, compared to December 31, 2024, largely influenced by a reduction in goodwill and intangible assets Condensed Consolidated Balance Sheet Highlights | Item | June 30, 2025 ($ thousand) | December 31, 2024 ($ thousand) | | :-------------------------------- | :------------------- | :--------------------- | | Cash and cash equivalents | 41,503 | 10,649 | | Total current assets | 571,351 | 594,915 | | Goodwill | 755,809 | 897,456 | | Intangible assets, net | 322,518 | 381,364 | | Total assets | 2,212,221 | 2,415,727 | | Total current liabilities | 573,643 | 545,785 | | Total liabilities | 1,604,625 | 1,709,107 | | Total stockholders' equity | 607,596 | 706,620 | - Total assets decreased by $203.5 million, and total stockholders' equity decreased by $99.0 million from December 31, 2024, to June 30, 202515 Condensed Consolidated Statements of Comprehensive Income (Loss) The company reported a significant net loss for both the three and six months ended June 30, 2025, a reversal from net income in the prior year, primarily driven by substantial goodwill and long-lived asset impairment losses Condensed Consolidated Statements of Comprehensive Income (Loss) Highlights | Item | Three Months Ended June 30, 2025 ($ thousand) | Three Months Ended June 30, 2024 ($ thousand) | Six Months Ended June 30, 2025 ($ thousand) | Six Months Ended June 30, 2024 ($ thousand) | | :------------------------------------ | :------------------------------------ | :------------------------------------ | :---------------------------------- | :---------------------------------- | | Revenue | 658,175 | 740,685 | 1,347,708 | 1,561,563 | | Gross profit | 196,399 | 229,827 | 394,519 | 487,333 | | Goodwill impairment loss | 109,515 | — | 109,515 | — | | Long-lived assets impairment loss | 18,262 | — | 18,262 | — | | Net income (loss) | (116,202) | 16,237 | (117,294) | 33,565 | | Basic EPS | (3.02) | 0.43 | (3.06) | 0.88 | | Diluted EPS | (3.02) | 0.42 | (3.06) | 0.88 | - Revenue decreased by 11.1% for the three months and 13.7% for the six months ended June 30, 2025, compared to the same periods in 202417 - The company incurred a goodwill impairment loss of $109.5 million and a long-lived assets impairment loss of $18.3 million in the first half of 202517 Condensed Consolidated Statements of Stockholders' Equity Stockholders' equity decreased from $706.6 million at December 31, 2024, to $607.6 million at June 30, 2025, primarily due to the net loss incurred during the period Condensed Consolidated Statements of Stockholders' Equity Highlights | Item | December 31, 2024 ($ thousand) | June 30, 2025 ($ thousand) | | :-------------------------------- | :--------------------- | :------------------- | | Total stockholders' equity | 706,620 | 607,596 | | Retained earnings | 1,304,696 | 1,187,402 | | Accumulated other comprehensive income (loss) | (11) | 195 | - Comprehensive income (loss) for the six months ended June 30, 2025, was a loss of $(117.1) million, compared to an income of $33.8 million for the same period in 202419 Condensed Consolidated Statements of Cash Flows Net cash provided by operating activities decreased year-over-year, while net cash used in investing and financing activities increased, resulting in a net decrease in cash, cash equivalents, and restricted cash for the six months ended June 30, 2025 Condensed Consolidated Statements of Cash Flows Highlights | Cash Flow Activity | Six Months Ended June 30, 2025 ($ thousand) | Six Months Ended June 30, 2024 ($ thousand) | | :------------------------------------------ | :---------------------------------- | :---------------------------------- | | Net cash provided by operating activities | 171,219 | 180,901 | | Net cash used in investing activities | (46,637) | (43,731) | | Net cash used in financing activities | (141,437) | (119,081) | | Net increase (decrease) in cash, cash equivalents and restricted cash | (16,855) | 18,089 | | Cash, cash equivalents and restricted cash at end of period | 72,450 | 126,362 | - The decrease in net cash from operating activities was primarily due to a smaller reduction in accounts receivable and subcontractor receivables compared to the prior year125 - Net cash used in investing activities increased due to a net purchase of investments of $26.9 million in 2025, compared to net proceeds of $4.5 million in 2024128 Notes to Unaudited Condensed Consolidated Financial Statements These notes provide detailed explanations of the accounting policies, significant estimates, and specific financial statement line items, including segment information, goodwill and intangible asset impairments, fair value measurements, and commitments 1. BASIS OF PRESENTATION This note outlines the basis for preparing the unaudited condensed consolidated financial statements, emphasizing U.S. GAAP compliance, the use of estimates, and details on cash, cash equivalents, restricted cash, and accounts receivable policies. It also mentions the adoption of ASU 2023-07 on segment reporting - The company adopted ASU 2023-07, 'Segment Reporting,' for the year ended December 31, 2024, expanding disclosure requirements for reportable segments28 Cash, Cash Equivalents and Restricted Cash Reconciliation | Item | June 30, 2025 ($ thousand) | December 31, 2024 ($ thousand) | | :------------------------------------------- | :------------------- | :--------------------- | | Cash and cash equivalents | 41,503 | 10,649 | | Restricted cash and cash equivalents (included in other current assets) | 22,146 | 14,984 | | Restricted cash, cash equivalents and investments | 44,141 | 71,840 | | Total cash, cash equivalents and restricted cash and investments | 107,790 | 97,473 | | Less restricted investments | (35,340) | (8,168) | | Total cash, cash equivalents and restricted cash | 72,450 | 89,305 | Allowance for Credit Losses for Accounts Receivable Activity | Item | 2025 ($ thousand) | 2024 ($ thousand) | | :------------------------------------ | :-------- | :-------- | | Balance as of January 1, | 32,421 | 32,233 | | Provision for expected credit losses | 4,655 | 6,195 | | Amounts written off charged against the allowance | (13,073) | (5,021) | | Allowance for credit losses in assets held for sale | (91) | — | | Balance as of June 30, | 23,912 | 33,407 | 2. HELD FOR SALE The company classified its Smart Square healthcare scheduling software as held for sale as of June 30, 2025, and completed its sale on July 1, 2025, for $65.3 million cash and a $10.0 million note. This disposal is not considered a discontinued operation - The sale of Smart Square healthcare scheduling software was completed on July 1, 2025, for $65.3 million in cash and a $10.0 million note37 Assets and Liabilities Classified as Held for Sale (June 30, 2025) | Item | Amount ($ thousand) | | :-------------------------- | :------------ | | Accounts receivable, net | 3,643 | | Fixed assets, net | 5,250 | | Intangible assets, net | 1,549 | | Goodwill | 32,132 | | Other assets | 97 | | Total assets held for sale | 42,671 | | Accounts payable and accrued expenses | 92 | | Deferred revenue | 6,540 | | Total liabilities held for sale | 6,632 | 3. REVENUE RECOGNITION Revenue is primarily generated from temporary staffing, permanent placement of healthcare professionals, and technology-enabled services. Recognition occurs when control of services is transferred, either on a gross basis (as principal) for its own network and language services, or a net basis (as agent) for subcontractor-based MSP and VMS arrangements - Revenue sources include temporary staffing, permanent placement of healthcare professionals, technology-enabled services (language interpretation, vendor management systems), and talent planning41 - Revenue is recorded on a gross basis when using its own network of healthcare professionals and for language services, and on a net basis when acting as an agent for subcontractors under MSP or VMS arrangements42 4. NET INCOME (LOSS) PER COMMON SHARE The company reported a basic and diluted net loss per common share for both the three and six months ended June 30, 2025, a significant decline from positive earnings per share in the prior year Net Income (Loss) Per Common Share | Period | 2025 Basic EPS | 2024 Basic EPS | 2025 Diluted EPS | 2024 Diluted EPS | | :-------------------------- | :------------- | :------------- | :--------------- | :--------------- | | Three Months Ended June 30, | $(3.02) | $0.43 | $(3.02) | $0.42 | | Six Months Ended June 30, | $(3.06) | $0.88 | $(3.06) | $0.88 | - Anti-dilutive potential common shares excluded from diluted weighted average common shares outstanding were 157 thousand for the three months and 110 thousand for the six months ended June 30, 202547 5. SEGMENT INFORMATION The company operates through three reportable segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. All segments experienced revenue declines for both the three and six months ended June 30, 2025, compared to the prior year, with varying impacts on gross profit margins - The company's three reportable segments are Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions48 Revenue by Reportable Segment (Three Months Ended June 30) | Segment | 2025 ($ thousand) | 2024 ($ thousand) | Change ($ thousand) | Change (%) | | :-------------------------- | :-------- | :-------- | :---------- | :--------- | | Nurse and Allied Solutions | 381,871 | 442,399 | (60,528) | (13.7%) | | Physician and Leadership Solutions | 174,531 | 186,065 | (11,534) | (6.2%) | | Technology and Workforce Solutions | 101,773 | 112,221 | (10,448) | (9.3%) | | Total Revenue | 658,175 | 740,685 | (82,510) | (11.1%) | Revenue by Reportable Segment (Six Months Ended June 30) | Segment | 2025 ($ thousand) | 2024 ($ thousand) | Change ($ thousand) | Change (%) | | :-------------------------- | :-------- | :-------- | :---------- | :--------- | | Nurse and Allied Solutions | 795,132 | 961,696 | (166,564) | (17.3%) | | Physician and Leadership Solutions | 348,596 | 374,862 | (26,266) | (7.0%) | | Technology and Workforce Solutions | 203,980 | 225,005 | (21,025) | (9.3%) | | Total Revenue | 1,347,708 | 1,561,563 | (213,855) | (13.7%) | Gross Margin by Reportable Segment (Three Months Ended June 30) | Segment | 2025 Gross Margin | 2024 Gross Margin | | :-------------------------- | :---------------- | :---------------- | | Nurse and Allied Solutions | 23.9% | 23.8% | | Physician and Leadership Solutions | 28.2% | 30.5% | | Technology and Workforce Solutions | 55.1% | 60.2% | 6. GOODWILL AND IDENTIFIABLE INTANGIBLE ASSETS The company recognized a $109.5 million goodwill impairment loss in the Physician and Leadership Solutions segment and an $18.3 million impairment loss on customer relationships intangible assets in the Nurse and Allied Solutions segment during the second quarter of 2025, driven by declines in forecasted revenue and increased costs - A goodwill impairment loss of $109.5 million was recognized for the Physician and Leadership Solutions segment due to lower-than-expected volume, gross margin pressures, and declining demand6162 - An impairment loss of $18.3 million was recognized on customer relationships intangible assets within the Nurse and Allied Solutions segment64 Goodwill Carrying Value by Reportable Segment (June 30, 2025) | Segment | Balance, January 1, 2025 ($ thousand) | Goodwill Impairment Loss ($ thousand) | Goodwill in Assets Held for Sale ($ thousand) | Balance, June 30, 2025 ($ thousand) | | :-------------------------------- | :---------------------------- | :---------------------------- | :---------------------------------- | :---------------------------- | | Nurse and Allied Solutions | 259,137 | — | — | 259,137 | | Physician and Leadership Solutions | 237,760 | (109,515) | — | 128,245 | | Technology and Workforce Solutions | 400,559 | — | (32,132) | 368,427 | | Total | 897,456 | (109,515) | (32,132) | 755,809 | 7. FAIR VALUE MEASUREMENT This note details the company's fair value measurement techniques for recurring and non-recurring assets and liabilities, utilizing Level 1 and Level 2 inputs for financial instruments and Level 3 inputs for impairment testing of intangible assets and goodwill. It also provides the fair value of its senior notes - The company uses Level 1 inputs for money market funds and deferred compensation, and Level 2 inputs for commercial paper and corporate bonds in recurring fair value measurements676869 Unobservable Inputs for Revenue Cycle Solutions Asset Group Fair Value Measurement (June 30, 2025) | Input | Range | Average | | :------------------------ | :------------ | :------ | | Revenue growth rates | (2.1)% - 6.1% | 3.3% | | Long-term growth rate | 3.5% | N/A | | Weighted-average cost of capital | 14.0% | N/A | Fair Value of Senior Notes (June 30, 2025) | Notes | Carrying Amount ($ thousand) | Estimated Fair Value ($ thousand) | | :---------- | :------------------- | :------------------------ | | 2027 Notes | 500,000 | 486,250 | | 2029 Notes | 350,000 | 322,875 | 8. INCOME TAXES The company is subject to taxation in various jurisdictions and is assessing the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements - The One Big Beautiful Bill Act (OBBBA) was enacted on July 4, 2025, and the company is currently assessing its impact on its consolidated financial statements80 - The company's effective income tax rate for the six months ended June 30, 2025, was 13%, down from 26% in the prior year, primarily due to a significant decline in income before income taxes and a goodwill impairment loss120 9. COMMITMENTS AND CONTINGENCIES The company is involved in various lawsuits, claims, and investigations in the ordinary course of business, including professional liability and class action lawsuits. Liabilities are accrued when an adverse outcome is probable and estimable - The company is involved in various legal proceedings, claims, and investigations related to professional liability, tax, compensation, contract, and employment-related matters81 - Accruals for loss contingencies are made when an adverse outcome is probable and the amount can be reasonably estimated, with significant matters including class and representative actions for wage and hour claims81 10. BALANCE SHEET DETAILS This note provides detailed breakdowns of various balance sheet accounts, including other current assets, fixed assets, other assets, accounts payable and accrued expenses, accrued compensation and benefits, and other current and long-term liabilities Other Current Assets (June 30, 2025) | Item | Amount ($ thousand) | | :-------------------------- | :------------ | | Restricted cash and cash equivalents | 22,146 | | Income taxes receivable | 10,592 | | Subcontractor deposits | 12,930 | | Other | 18,698 | | Total Other current assets | 64,366 | Fixed Assets, Net (June 30, 2025) | Item | Amount ($ thousand) | | :-------------------------- | :------------ | | Furniture and equipment | 95,254 | | Software | 427,187 | | Leasehold improvements | 16,058 | | Accumulated depreciation | (380,284) | | Fixed assets, net | 158,215 | Accounts Payable and Accrued Expenses (June 30, 2025) | Item | Amount ($ thousand) | | :-------------------------- | :------------ | | Trade accounts payable | 34,740 | | Subcontractor payable | 64,716 | | Accrued expenses | 53,420 | | Loss contingencies | 7,213 | | Professional liability reserve | 9,075 | | Other | 6,459 | | Total | 175,623 | Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section discusses AMN Healthcare's business overview, market trends, critical accounting policies, and financial results, highlighting revenue declines, impairment losses, and liquidity Overview of Our Business AMN Healthcare provides technology-enabled healthcare workforce solutions and staffing services across three reportable segments: nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. The company reported consolidated revenue declines for both the three and six months ended June 30, 2025 - AMN Healthcare provides technology-enabled healthcare workforce solutions and staffing services to healthcare organizations84 - The company operates through three reportable segments: nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions85 Consolidated Revenue Overview | Period | 2025 ($ thousand) | 2024 ($ thousand) | | :-------------------------- | :-------- | :-------- | | Three Months Ended June 30, | 658,200 | 740,700 | | Six Months Ended June 30, | 1,347,700 | 1,561,600 | Operating Metrics The company monitors key operating metrics such as average travelers on assignment, bill rates, billable hours, days filled, revenue per day filled, and minutes for language services to evaluate performance and understand operational trends - Key operating metrics include average travelers on assignment, bill rates, billable hours (nurse and allied solutions), days filled, revenue per day filled (physician and leadership solutions), and minutes (language services)96 Recent Trends Post-COVID-19, healthcare organizations are shifting focus to permanent staff hiring and cost management, leading to decreased demand in travel nurse staffing and slowing growth in language services due to increased competition and pricing pressure. Visa retrogression also impacted international nurse staffing - Healthcare organizations are focusing on hiring permanent staff, implementing cost management strategies, and exploring alternative staffing models to decrease reliance on contingent labor91 - Demand in the travel nurse business decreased in Q2 2025 due to seasonal fluctuations and lower overall market demand, with open orders dropping below prior year levels91 - Growth in the language services business has slowed due to reduced minute growth and lower pricing, a result of increased market competition94 Critical Accounting Policies and Estimates There have been no material changes to the company's critical accounting policies and estimates compared to its 2024 Annual Report. Management continues to evaluate estimates related to intangible assets, asset impairments, self-insurance, compensation, accounts receivable, contingencies, and income taxes - No material changes have occurred in critical accounting policies and estimates compared to the 2024 Annual Report95 - Key estimates include those related to intangible assets, asset impairments, accruals for self-insurance, compensation, accounts receivable, contingencies and litigation, contingent consideration, and income taxes95 Results of Operations The company experienced significant declines in revenue and gross profit across all segments for both the three and six months ended June 30, 2025, compared to the prior year. This was exacerbated by substantial goodwill and long-lived asset impairment losses, leading to a net loss Overall Performance The company's overall financial performance shifted from net income to a net loss for both the three and six months ended June 30, 2025, with net income (loss) as a percentage of revenue significantly declining Net Income (Loss) as a Percentage of Revenue | Period | 2025 | 2024 | | :-------------------------- | :----- | :----- | | Three Months Ended June 30, | (17.7)% | 2.2% | | Six Months Ended June 30, | (8.7)% | 2.1% | Comparison of Results for the Three Months Ended June 30, 2025 to the Three Months Ended June 30, 2024 Total revenue decreased 11% to $658.2 million, primarily due to a 14% decline in the nurse and allied solutions segment. Gross profit decreased 15%, and significant goodwill and long-lived asset impairment losses were recognized, leading to a net loss of $(116.2) million - Total revenue decreased 11% to $658.2 million, with the nurse and allied solutions segment experiencing the greatest decline99 - Nurse and allied solutions segment revenue decreased 14% ($60.5 million) due to a 16% decrease in average travelers on assignment, a 2% decrease in average bill rate, and a 1% decrease in average billable hours, partially offset by a $15.0 million increase in labor disruption revenue99 - Physician and leadership solutions segment revenue decreased 6% ($11.6 million) due to lower demand across all businesses, including a 9% decrease in locum tenens days filled, a 25% decline in interim leadership, and a 29% decline in physician permanent placement and executive search100 - Technology and workforce solutions segment revenue decreased 9% ($10.4 million) primarily due to declines in VMS (31%) and outsourced solutions (46%) businesses101 - Gross profit decreased 15% to $196.4 million, with consolidated gross margin declining to 29.8% from 31.0% in the prior year104 - A goodwill impairment loss of $109.5 million and a long-lived assets impairment loss of $18.3 million were recognized106107 Comparison of Results for the Six Months Ended June 30, 2025 to the Six Months Ended June 30, 2024 Total revenue decreased 14% to $1,347.7 million, primarily driven by a 17% decline in the nurse and allied solutions segment. Gross profit decreased 19%, and significant impairment losses contributed to a net loss of $(117.3) million - Total revenue decreased 14% to $1,347.7 million, with the nurse and allied solutions segment experiencing the greatest decline110 - Nurse and allied solutions segment revenue decreased 17% ($166.6 million) due to a 19% decrease in average travelers on assignment, a 3% decrease in average bill rate, and a 1% decrease in average billable hours, partially offset by a $54.0 million increase in labor disruption revenue111 - Physician and leadership solutions segment revenue decreased 7% ($26.3 million) due to lower demand, including a 2% decline in locum tenens revenue (9% decrease in days filled, partially offset by 8% increase in revenue per day filled), a 23% decline in interim leadership, and a 29% decline in physician permanent placement and executive search112 - Technology and workforce solutions segment revenue decreased 9% ($21.0 million) due to declines in VMS (32%) and outsourced solutions (51%), partially offset by a 3% growth in language services (7% increase in minutes)113 - Gross profit decreased 19% to $394.5 million, with consolidated gross margin declining to 29.3% from 31.2% in the prior year116 - A goodwill impairment loss of $109.5 million and a long-lived assets impairment loss of $18.3 million were recognized118 Liquidity and Capital Resources Net cash provided by operating activities decreased, while net cash used in investing and financing activities increased for the six months ended June 30, 2025. The company maintains a $750.0 million secured revolving credit facility and believes its current liquidity and available borrowings are sufficient to fund operations and future acquisitions Cash Flow Summary (Six Months Ended June 30) | Item | 2025 ($ thousand) | 2024 ($ thousand) | | :-------------------------------------------------- | :-------- | :-------- | | Net cash provided by operating activities | 171,219 | 180,901 | | Net cash used in investing activities | (46,637) | (43,731) | | Net cash used in financing activities | (141,437) | (119,081) | | Net increase (decrease) in cash, cash equivalents and restricted cash | (16,855) | 18,089 | - As of June 30, 2025, $70.0 million was drawn with $659.6 million available under the $750.0 million secured revolving credit facility123 - The company had $500.0 million in 2027 Notes and $350.0 million in 2029 Notes outstanding as of June 30, 2025123 - Days Sales Outstanding (DSO) was 54 days as of June 30, 2025, an improvement from 63 days as of June 30, 2024127 Recent Accounting Pronouncements The company is evaluating the impact of two new FASB ASUs: ASU 2023-09 on Income Tax Disclosures (effective for fiscal years beginning after December 15, 2024) and ASU 2024-03 on Expense Disaggregation Disclosures (effective for fiscal years beginning after December 15, 2026) - ASU 2023-09, 'Income Taxes (Topic 740): Improvements to Income Tax Disclosures,' is effective for fiscal years beginning after December 15, 2024132 - ASU 2024-03, 'Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,' is effective for fiscal years beginning after December 15, 2026133 Item 3. Quantitative and Qualitative Disclosures about Market Risk The company's primary market risk exposure is interest rate risk associated with its variable interest debt and investment portfolio. A 100 basis point change in interest rates is not expected to materially affect its financial statements or investment portfolio. Foreign currency risk is considered immaterial - The primary market risk exposure is interest rate risk associated with variable interest debt instruments and the investment portfolio136 - A 100 basis point increase in interest rates would not result in a material effect on the unaudited condensed consolidated financial statements or the fair value of the investment portfolio136 - Foreign currency risk is considered immaterial as substantially all revenue is generated in the United States137 Item 4. Controls and Procedures Management, including the CEO and CFO/COO, concluded that the company's disclosure controls and procedures were effective as of June 30, 2025. No material changes in internal control over financial reporting occurred during the quarter - Management concluded that disclosure controls and procedures were effective as of June 30, 2025139 - No material changes in internal control over financial reporting occurred during the quarter ended June 30, 2025140 PART II - OTHER INFORMATION This part covers legal proceedings, risk factors, equity security sales, defaults, mine safety, other information, and exhibits Item 1. Legal Proceedings Information regarding legal proceedings is incorporated by reference from Note (9), 'Commitments and Contingencies,' in the financial statements - Information on legal proceedings is incorporated by reference from Note (9), 'Commitments and Contingencies,' in the accompanying financial statements142 Item 1A. Risk Factors There have been no material changes to the risk factors disclosed in the 2024 Annual Report. Various factors, including economic downturns, market conditions, regulatory compliance, and asset impairments, could materially affect the company's business and financial results - No material changes to the risk factors disclosed in Part I, Item 1A of the 2024 Annual Report143 - Key risk factors include client efficiency, economic downturns, government policies, market consolidation, legal proceedings, regulatory compliance, immigration laws, recruitment/retention, technology disruptions, cybersecurity, AI, acquisitions, brand reputation, goodwill/intangible asset impairment, indebtedness, and insurance accruals135138 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds The company has a share repurchase program with $226.7 million remaining authorization as of June 30, 2025. No shares of common stock were repurchased during the six months ended June 30, 2025 - The company's share repurchase program has a total authorization of $1,350.0 million, with $226.7 million remaining as of June 30, 2025144 - No shares of common stock were repurchased during the six months ended June 30, 2025145 Item 3. Defaults Upon Senior Securities The company reported no defaults upon senior securities Item 4. Mine Safety Disclosures This item is not applicable to the company Item 5. Other Information No directors or officers adopted, modified, or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the three months ended June 30, 2025 - No Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were adopted, modified, or terminated by directors or officers during the three months ended June 30, 2025148 Item 6. Exhibits This section lists the exhibits filed with the Quarterly Report, including various certifications and XBRL documents - Exhibits include certifications (31.1, 31.2, 32.1, 32.2) and XBRL Instance, Schema, Calculation, Definition, Label, and Presentation Documents149 Signatures The report is signed by Caroline S. Grace, President and Chief Executive Officer, and Brian M. Scott, Chief Financial Officer and Chief Operating Officer, on August 7, 2025 - The report was signed by Caroline S. Grace (President and CEO) and Brian M. Scott (CFO and COO) on August 7, 2025152
AMN Healthcare Services(AMN) - 2025 Q2 - Quarterly Report